最新 Form 144 申報
公司的高階主管、董事與其他關係人要賣出受限制股票或控制股份，而且三個月內預計賣出超過 5,000 股或 5 萬美元時，下單時要交 Form 144。它是預計賣出的通知；高階主管、董事實際賣出之後，會再申報 Form 4。13D、13G 與 Form 144 是什麼
Form 144 申報
由新到舊。有 Form 144/A 修正的申報只列修正後的那一份。
近 365 天的申報（依美東日期）。
本站的 Form 144 申報：2023/1/4 到 2026/10/5。
市值明顯填錯的申報不列在這裡，也不算進合計；公司的頁面照樣列出並加註。判斷方式是把市值除以股數，得到的每股價格遠高於這家公司在預計賣出日前後的 Form 4 成交價與 13F 持股的價格，就當成填錯。
- 申報份數
- 413
- 預計賣出市值
- $14.1 億
- 賣方
- 117
- 公司
- 37
- 依 10b5-1 計畫
- 220
| 公司 | 申報時間（美東） | 賣方 | 預計賣出股數 | 市值 | 預計賣出日 | 券商 | 原文 |
|---|---|---|---|---|---|---|---|
| ADPTAdaptive Biotechnologies Corp | 2026/3/1620:53 ET | Piskel Kyle高階主管 | 1.87 萬 | $27.1 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1620:46 ET | Rubinstein Julie高階主管 | 12.3 萬 | $177.9 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1620:40 ET | Robins Harlan S高階主管 | 47.0 萬 | $682.8 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1620:33 ET | Robins Chad M高階主管 · 董事 | 47.0 萬 | $682.7 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC | SEC |
| MPMP Materials Corp. | 2026/3/1616:11 ET | Elliot Hoops高階主管 | 1.39 萬 | $83.5 萬 | 2026/3/1610b5-1 | Merrill | SEC |
| IOTSamsara Inc. | 2026/3/1316:20 ET | Kirchhoff Benjamin Louis高階主管 | 2,480 | $7.91 萬 | 2026/3/1310b5-1 | Charles Schwab & Co., Inc. | SEC |
| UHSUniversal Health Services Inc | 2026/3/1316:06 ET | Elliot Sussman董事 | 356 | $6.88 萬 | 2026/3/13 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| UHSUniversal Health Services Inc | 2026/3/1116:55 ET | Elliot Sussman董事 | 318 | $5.93 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1116:42 ET | Francis Lo高階主管 | 3.06 萬 | $44.4 萬 | 2026/3/1110b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1116:21 ET | Michelle Griffin董事 | 1.54 萬 | $21.4 萬 | 2026/3/11 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/1019:53 ET | Lo Francis高階主管 | 3.81 萬 | $62.6 萬 | 2026/3/5 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| LPLALPL Financial Holdings Inc. | 2026/3/1011:36 ET | Cohen Marc Eliot高階主管 | 1,089 | $33.7 萬 | 2026/3/10 | Fidelity Brokerage Services LLC | SEC |
| LPLALPL Financial Holdings Inc. | 2026/3/916:13 ET | Cohen Marc Eliot高階主管 | 2,212 | $68.3 萬 | 2026/3/9 | Fidelity Brokerage Services LLC | SEC |
| KRYSKrystal Biotech, Inc. | 2026/3/416:40 ET | Suma Krishnan董事 · 高階主管 · 持股 10% 以上股東 | 2.50 萬 | $659.5 萬 | 2026/3/410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| KRYSKrystal Biotech, Inc. | 2026/3/416:39 ET | Krish Krishnan董事 · 高階主管 · 持股 10% 以上股東 | 2.50 萬 | $659.5 萬 | 2026/3/410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/316:59 ET | Harlan Robins高階主管 | 1.42 萬 | $22.9 萬 | 2026/3/310b5-1 | Goldman Sachs & Co. LLC | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/316:59 ET | Chad Robins高階主管 | 5.31 萬 | $85.4 萬 | 2026/3/310b5-1 | Goldman Sachs & Co. LLC | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/316:50 ET | Julie Rubinstein高階主管 | 120.7 萬 | $1,945 萬 | 2026/3/310b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/316:50 ET | Michelle Griffin董事 | 4.80 萬 | $77.4 萬 | 2026/3/310b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| ASPIASP Isotopes Inc. | 2026/3/221:45 ET | Mann Paul Elliot董事 · 高階主管 | 16.2 萬 | $86.6 萬 | 2026/3/210b5-1 | Independent Trading Group (ITG) Inc. | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/218:48 ET | Masaru Matsuda高階主管 | 1.21 萬 | $31.4 萬 | 2026/3/210b5-1 | Merrill Lynch | SEC |
| ATRAAtara Biotherapeutics, Inc. | 2026/3/218:25 ET | Nguyen AnhCo董事 · 高階主管 | 3,355 | $1.82 萬 | 2026/3/2 | Morgan Stanley Smith Barney LLC | SEC |
| ATRAAtara Biotherapeutics, Inc. | 2026/3/218:24 ET | Grant-Huerta Yanina高階主管 | 2,355 | $1.28 萬 | 2026/3/2 | Morgan Stanley Smith Barney LLC | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/218:22 ET | Larry Todd Edwards高階主管 | 3,687 | $9.28 萬 | 2026/3/2 | Merrill Lynch | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/218:22 ET | Todd Watanabe高階主管 | 3.73 萬 | $94.1 萬 | 2026/3/2 | Merrill Lynch | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/218:22 ET | Latha Vairavan高階主管 | 2,853 | $7.18 萬 | 2026/3/2 | Merrill Lynch | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/218:21 ET | Patrick Burnett高階主管 | 6,287 | $15.8 萬 | 2026/3/2 | Merrill Lynch | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/217:59 ET | Keith LeonardBoard of Director | 3.93 萬 | $99.7 萬 | 2026/3/210b5-1 | Merrill | SEC |
| ARQTArcutis Biotherapeutics, Inc. | 2026/3/217:25 ET | Howard Welgus董事 | 1.00 萬 | $25.7 萬 | 2026/3/210b5-1 | Merrill | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/217:24 ET | Harlan Robins高階主管 | 1.00 萬 | $16.1 萬 | 2026/3/210b5-1 | Goldman Sachs & Co. LLC | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/3/217:24 ET | Chad Robins高階主管 | 28.9 萬 | $465.9 萬 | 2026/3/210b5-1 | Goldman Sachs & Co. LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/3/216:35 ET | Vicki Lee Sato董事 | 8.80 萬 | $80.0 萬 | 2026/3/210b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| KRYSKrystal Biotech, Inc. | 2026/3/212:56 ET | Romano Kathryn高階主管 | 750 | $20.1 萬 | 2026/3/210b5-1 | Fidelity Brokerage Services LLC | SEC |
| ADPTAdaptive Biotechnologies Corp | 2026/2/2716:47 ET | Chad Robins高階主管 | 18.3 萬 | $293.0 萬 | 2026/2/2710b5-1 | Goldman Sachs & Co. LLC | SEC |
| KRYSKrystal Biotech, Inc. | 2026/2/2716:41 ET | Daniel S Janney董事 | 1.18 萬 | $325.3 萬 | 2026/2/2710b5-1 | Merrill Lynch | SEC |
| KRYSKrystal Biotech, Inc. | 2026/2/2616:41 ET | Daniel S Janney董事 | 7,741 | $213.4 萬 | 2026/2/2610b5-1 | Merrill Lynch | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2521:00 ET | SVF Endurance (Cayman) Limited股東 | 40.0 萬 | $379.6 萬 | 2026/2/25 | Citigroup Global Markets Inc. | SEC |
| KRYSKrystal Biotech, Inc. | 2026/2/2516:38 ET | Daniel S Janney董事 | 700 | $19.3 萬 | 2026/2/2510b5-1 | Merrill Lynch | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2510:48 ET | de Verneuil Vanina高階主管 | 1.37 萬 | $13.5 萬 | 2026/2/2510b5-1 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2509:48 ET | Eisner Mark高階主管 | 1,889 | $1.85 萬 | 2026/2/2510b5-1 | Fidelity Brokerage Services LLC | SEC |
| KRYSKrystal Biotech, Inc. | 2026/2/2417:20 ET | Janney Daniel董事 | 3.79 萬 | $1,011 萬 | 2026/2/2410b5-1 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2417:16 ET | Eisner Mark高階主管 | 1,616 | $1.54 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2417:07 ET | De Backer Marianne高階主管 · 董事 | 1.48 萬 | $14.1 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2416:57 ET | O'Byrne Jason高階主管 | 1,634 | $1.56 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2416:53 ET | Sabatini Brent高階主管 | 1,430 | $1.36 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2416:42 ET | de Verneuil Vanina高階主管 | 3,117 | $2.97 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| KRYSKrystal Biotech, Inc. | 2026/2/2416:39 ET | Daniel S Janney董事 | 1.38 萬 | $371.0 萬 | 2026/2/2410b5-1 | Merrill Lynch | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2416:33 ET | Vicki Lee Sato董事 | 2.04 萬 | $15.1 萬 | 2026/2/2410b5-1 | Morgan Stanley Smith Barney LLC Executive Financial Services | SEC |
| FTHFaeth Therapeutics, Inc. | 2026/2/2416:11 ET | Celebi John前高階主管 | 3,374 | $11.6 萬 | 2026/2/24 | Fidelity Brokerage Services LLC | SEC |
| VIRVir Biotechnology, Inc. | 2026/2/2316:52 ET | O'Byrne Jason高階主管 | 2,089 | $1.56 萬 | 2026/2/23 | Fidelity Brokerage Services LLC | SEC |